Subgroup analyses revealed that the prevalence of elevated ALT in patients with severe COVID-19 was 30% (95% CI: 0.24, 0.38), which was significantly higher than that in patients with non-severe cases (15%; 95% CI: 0.07, 0.25) (p = 0.011 for subgroup difference; Figure 4). Here, GPT is linked to COVID-19.